TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Catherine Thieblemont et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.